Enliven Therapeutics (NASDAQ:ELVN) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) in a report issued on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $37.00 target price on the stock. HC Wainwright also issued estimates for Enliven Therapeutics’ Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.49) […]